First Time Loading...

Human Metabolome Technologies Inc
TSE:6090

Watchlist Manager
Human Metabolome Technologies Inc Logo
Human Metabolome Technologies Inc
TSE:6090
Watchlist
Price: 650 JPY -0.61% Market Closed
Updated: May 1, 2024

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Human Metabolome Technologies Inc

Revenue
1.3B JPY
Cost of Revenue
-462.1m JPY
Gross Profit
859.5m JPY
Operating Expenses
-661.3m JPY
Operating Income
198.2m JPY
Other Expenses
84.4m JPY
Net Income
282.6m JPY

Margins Comparison
Human Metabolome Technologies Inc Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
JP
Human Metabolome Technologies Inc
TSE:6090
3.8B JPY
65%
15%
21%
US
Thermo Fisher Scientific Inc
NYSE:TMO
220.8B USD
40%
17%
14%
US
Danaher Corp
NYSE:DHR
181.6B USD
58%
22%
18%
US
IQVIA Holdings Inc
NYSE:IQV
41.8B USD
35%
14%
9%
US
Agilent Technologies Inc
NYSE:A
40.2B USD
51%
19%
18%
KR
Samsung Biologics Co Ltd
KRX:207940
55.6T KRW
49%
30%
23%
CH
Lonza Group AG
SIX:LONN
36.8B CHF
36%
20%
10%
US
Mettler-Toledo International Inc
NYSE:MTD
26.3B USD
59%
29%
21%
US
West Pharmaceutical Services Inc
NYSE:WST
26.3B USD
38%
24%
20%
IE
ICON PLC
NASDAQ:ICLR
24.6B USD
30%
13%
8%
FR
Sartorius Stedim Biotech SA
PAR:DIM
18.7B EUR
43%
15%
9%
Country JP
Market Cap 3.8B JPY
Gross Margin
65%
Operating Margin
15%
Net Margin
21%
Country US
Market Cap 220.8B USD
Gross Margin
40%
Operating Margin
17%
Net Margin
14%
Country US
Market Cap 181.6B USD
Gross Margin
58%
Operating Margin
22%
Net Margin
18%
Country US
Market Cap 41.8B USD
Gross Margin
35%
Operating Margin
14%
Net Margin
9%
Country US
Market Cap 40.2B USD
Gross Margin
51%
Operating Margin
19%
Net Margin
18%
Country KR
Market Cap 55.6T KRW
Gross Margin
49%
Operating Margin
30%
Net Margin
23%
Country CH
Market Cap 36.8B CHF
Gross Margin
36%
Operating Margin
20%
Net Margin
10%
Country US
Market Cap 26.3B USD
Gross Margin
59%
Operating Margin
29%
Net Margin
21%
Country US
Market Cap 26.3B USD
Gross Margin
38%
Operating Margin
24%
Net Margin
20%
Country IE
Market Cap 24.6B USD
Gross Margin
30%
Operating Margin
13%
Net Margin
8%
Country FR
Market Cap 18.7B EUR
Gross Margin
43%
Operating Margin
15%
Net Margin
9%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Human Metabolome Technologies Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
JP
Human Metabolome Technologies Inc
TSE:6090
3.8B JPY
17%
13%
12%
34%
US
Thermo Fisher Scientific Inc
NYSE:TMO
220.8B USD
13%
6%
9%
8%
US
Danaher Corp
NYSE:DHR
181.6B USD
16%
10%
12%
10%
US
IQVIA Holdings Inc
NYSE:IQV
41.8B USD
23%
5%
10%
9%
US
Agilent Technologies Inc
NYSE:A
40.2B USD
21%
11%
14%
14%
KR
Samsung Biologics Co Ltd
KRX:207940
55.6T KRW
9%
5%
9%
6%
CH
Lonza Group AG
SIX:LONN
36.8B CHF
7%
4%
9%
8%
US
Mettler-Toledo International Inc
NYSE:MTD
26.3B USD
-1 261%
23%
48%
28%
US
West Pharmaceutical Services Inc
NYSE:WST
26.3B USD
21%
16%
23%
22%
IE
ICON PLC
NASDAQ:ICLR
24.6B USD
7%
4%
7%
6%
FR
Sartorius Stedim Biotech SA
PAR:DIM
18.7B EUR
8%
4%
7%
5%
Country JP
Market Cap 3.8B JPY
ROE
17%
ROA
13%
ROCE
12%
ROIC
34%
Country US
Market Cap 220.8B USD
ROE
13%
ROA
6%
ROCE
9%
ROIC
8%
Country US
Market Cap 181.6B USD
ROE
16%
ROA
10%
ROCE
12%
ROIC
10%
Country US
Market Cap 41.8B USD
ROE
23%
ROA
5%
ROCE
10%
ROIC
9%
Country US
Market Cap 40.2B USD
ROE
21%
ROA
11%
ROCE
14%
ROIC
14%
Country KR
Market Cap 55.6T KRW
ROE
9%
ROA
5%
ROCE
9%
ROIC
6%
Country CH
Market Cap 36.8B CHF
ROE
7%
ROA
4%
ROCE
9%
ROIC
8%
Country US
Market Cap 26.3B USD
ROE
-1 261%
ROA
23%
ROCE
48%
ROIC
28%
Country US
Market Cap 26.3B USD
ROE
21%
ROA
16%
ROCE
23%
ROIC
22%
Country IE
Market Cap 24.6B USD
ROE
7%
ROA
4%
ROCE
7%
ROIC
6%
Country FR
Market Cap 18.7B EUR
ROE
8%
ROA
4%
ROCE
7%
ROIC
5%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More